Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan + oxaliplatin + fluorouracil
- Development stage
- Unknown
- Lead developer
- Association pour la Recherche sur le Temps Biologique et la Chronothérapie
- Modality
- Small Molecules
- Administration
- Intra-arterial
01
Overview
HAI chronomodulated chemotherapy is a regional combination chemotherapy regimen delivered via hepatic artery infusion (HAI) according to circadian rhythms (chronomodulation). The regimen typically consists of a triplet of small molecule agents: irinotecan, oxaliplatin, and 5-fluorouracil (5-FU). It is primarily developed by the Association pour la Recherche sur le Temps Biologique et la Chronothérapie (ARTBC) for the treatment of colorectal cancer with unresectable liver metastases. The chronomodulated delivery aims to synchronize drug administration with the body's biological clock to maximize efficacy and minimize toxicity. In clinical studies like the OPTILIV trial, this HAI triplet has been evaluated in combination with systemic cetuximab to improve surgical resection rates.
- Other names
- HAI chronomodulated chemotherapychronomodulated HAI tripletHAI-oxaliplatin/irinotecan/5-FUOPTILIV regimen
02
Targets
TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on irinotecan + oxaliplatin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan + oxaliplatin + fluorouracil.